بدائل البحث:
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
site decrease » sizes decrease (توسيع البحث), step decrease (توسيع البحث), rate decreased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
_ largest » _ large (توسيع البحث)
largest decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث)
small decrease » small increased (توسيع البحث)
site decrease » sizes decrease (توسيع البحث), step decrease (توسيع البحث), rate decreased (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), a decrease (توسيع البحث), mean decrease (توسيع البحث)
_ largest » _ large (توسيع البحث)
-
1
-
2
-
3
Data and code from: Continental declines in North American small mammal populations
منشور في 2025الموضوعات: -
4
Table 1_Demethylase FTO mediates m6A modification of ENST00000619282 to promote apoptosis escape in rheumatoid arthritis and the intervention effect of Xinfeng Capsule.docx
منشور في 2025"…Bioinformatics prediction, MeRIP-qPCR, RIP, and RNA pull-down assays were employed to identify the m6A modification sites of ENST00000619282 and their interactions with FTO/YTHDF1. …"
-
5
-
6
-
7
-
8
Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA.
منشور في 2025الموضوعات: -
9
-
10
The m6A reader YTHDF2 protects vascular smooth muscle cells against the osteogenic differentiation through targeting Runx2
منشور في 2025"…These results suggest that YTHDF2 directly binds to the m6A modification site of Runx2 to mediate the mRNA degradation that prevents VC by inhibiting the osteogenic development of VSMCs. …"
-
11
-
12
-
13
-
14
Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses
منشور في 2025الموضوعات: -
15
-
16
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
منشور في 2025"…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
-
17
-
18
-
19
-
20